Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.
Nakanjako D, Kiragga AN, Musick BS, Yiannoutsos CT, Wools-Kaloustian K, Diero L, Oyaro P, Lugina E, Ssali JC, Kambugu A, Easterbrook P. Nakanjako D, et al. Among authors: easterbrook p. AIDS. 2016 Jul 31;30(12):1913-22. doi: 10.1097/QAD.0000000000001085. AIDS. 2016. PMID: 26959510 Free PMC article.
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.
Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D; UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Phillips AN, et al. Among authors: easterbrook p. AIDS. 2005 Mar 25;19(5):487-94. doi: 10.1097/01.aids.0000162337.58557.3d. AIDS. 2005. PMID: 15764854
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.
Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A; UK Collaborative HIV Cohort Study. Phillips AN, et al. Among authors: easterbrook p. AIDS. 2007 Aug 20;21(13):1717-21. doi: 10.1097/QAD.0b013e32827038bf. AIDS. 2007. PMID: 17690569
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.
Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T, Fisher M, Walsh J, Pillay D, Bansi L, Gazzard B, Easterbrook P, Gilson R, Johnson M, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study. Phillips AN, et al. Among authors: easterbrook p. Lancet. 2007 Dec 8;370(9603):1923-8. doi: 10.1016/S0140-6736(07)61815-7. Lancet. 2007. PMID: 18068516
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study. Bansi LK, et al. Among authors: easterbrook p. AIDS. 2008 Jan 30;22(3):349-56. doi: 10.1097/QAD.0b013e3282f4709a. AIDS. 2008. PMID: 18195561
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.
United Kingdom Collaborative HIV Cohort Study; Lee KJ, Dunn D, Gilson R, Porter K, Bansi L, Hill T, Phillips AN, Sabin CA, Schwenk A, Leen C, Delpech V, Anderson J, Gazzard B, Johnson M, Easterbrook P, Walsh J, Fisher M, Orkin C. United Kingdom Collaborative HIV Cohort Study, et al. Among authors: easterbrook p. AIDS. 2008 Oct 1;22(15):1943-50. doi: 10.1097/QAD.0b013e32830e4cf3. AIDS. 2008. PMID: 18784458
339 results